Skip to main content
    B

    Briacell Therapeutics Corp (BCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.30
    -0.09 (-2.65%)

    Market Cap: $29.60M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Briacell Therapeutics Corp (BCTX) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    Briacell Therapeutics reported revenue of $0 for the fiscal year ended Jul 31, 2026. That year, net income was -$35.33M, operating cash flow was -$28.65M and free cash flow was -$28.78M. The quarter ended Apr 30, 2026 had revenue of $0 and net income of -$7.24M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jul 2026, with an operating loss of $36.05M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jul 2026$0N/AN/AN/AN/A
    Jul 2025$0N/AN/AN/AN/A
    Jul 2024$0N/AN/AN/AN/A
    Jul 2023$0N/AN/AN/AN/A
    Jul 2022$0N/AN/AN/AN/A
    Jul 2021$0N/AN/AN/AN/A
    Jul 2020$0N/AN/AN/AN/A
    Jul 2019$0N/AN/AN/AN/A
    Jul 2018$0N/AN/AN/AN/A
    Jul 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Jul 2017 to Jul 2026

    Income Statement

    In the fiscal year ended Jul 2026, the net loss widened from the year before. In the quarter ended Apr 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemJul 2026Jul 2025Jul 2024Jul 2023Jul 2022Jul 2021Jul 2020Jul 2019Jul 2018Jul 2017
    Cost of revenue$0$0$0$0$0$0$85.10K$18.83K$16.88KN/A
    Gross profit$0$0$0$0$0$0-$85.10K-$18.83K-$16.88K-$289
    Research and development$29.24M$21.27M$27.18M$15.34M$8.02M$2.02M$2.43M$4.94M$3.11M$2.12M
    Operating income-$36.05M-$27.20M-$33.33M-$23.27M-$15.29M-$6.98M-$4.02M-$6.25M-$4.97M-$3.21M
    Net income-$35.33M-$26.56M-$4.93M-$20.30M-$26.84M-$13.82M-$4.02M-$5.82MN/A-$3.22M
    EBITDA-$35.03M-$26.23M-$4.74M-$20.29MN/AN/AN/A-$5.77MN/AN/A
    Fiscal years ended Jul 2017 to Jul 2026

    Quarterly

    Line itemApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Revenue$0$0$0$225.34K$0$0$0$22.67K$0$0$0$0
    Gross profit$0-$27.14K$0-$36.43K$0$0$0-$71.85K$0$0$0-$3.86K
    Operating income-$7.62M-$7.67M-$8.32M-$8.55M-$6.33M-$7.17M-$5.15M-$5.77M-$9.23M-$9.83M-$8.50M-$7.71M
    Net income-$7.24M-$7.35M-$8.28M-$8.16M-$6.22M-$6.34M-$5.83M-$1.25M$1.69M-$11.33M$5.96M-$2.42M
    Last 12 quarters

    Balance Sheet

    As of Jul 2026, cash and equivalents of $9.85M were 41.8% of total assets of $23.58M, against total liabilities of $8.02M.

    Annual

    Line itemJul 2026Jul 2025Jul 2024Jul 2023Jul 2022Jul 2021Jul 2020Jul 2019Jul 2018Jul 2017
    Total assets$23.58M$21.65M$5.87M$27.16M$42.58M$58.04M$522.33K$444.66K$2.28M$1.64M
    Current assets$22.04M$19.93M$3.65M$26.95M$42.35M$57.80M$238.95K$165.72K$1.88M$1.63M
    Cash and equivalents$9.85M$10.49M$862.09K$21.25M$41.04M$57.27M$21.25K$157.03K$720.26K$1.01M
    Total liabilities$8.02M$4.32M$8.56M$30.94M$32.25M$30.37M$4.12M$1.13M$1.34M$885.90K
    Short-term debtN/AN/AN/AN/AN/AN/A$249.80K$322.53K$1.12MN/A
    Long-term debtN/AN/AN/AN/AN/A$25.99K$155.94K$0N/AN/A
    Shareholder equity$16.40M$17.88M-$2.38M-$3.78M$10.33M$27.67M$14.57M$14.06M$945.02K$750.23K
    Fiscal years ended Jul 2017 to Jul 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Total assets$23.58M$27.07M$33.59M$13.08M$29.77M$17.00M$9.36M$10.41M$8.15M$6.20M$12.23M$18.62M
    Total liabilities$8.02M$3.66M$3.38M$3.72M$5.93M$5.06M$6.14M$6.70M$11.88M$12.44M$20.55M$16.10M
    Cash and equivalents$9.85M$6.88M$29.90M$2.71M$14.43M$12.46M$5.01M$5.79M$1.20M$935.69K$6.24M$13.65M
    Shareholder equity$16.40M$24.06M$30.73M$9.98M$24.58M$12.42M$3.60M$4.04M-$3.31M-$5.97M-$8.07M$2.72M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jul 2026.

    Annual

    Line itemJul 2026Jul 2025Jul 2024Jul 2023Jul 2022Jul 2021Jul 2020Jul 2019Jul 2018Jul 2017
    Operating cash flow-$28.65M-$28.17M-$24.13M-$23.74M-$12.48M-$7.75M-$1.31M-$5.12M-$4.95M-$1.91M
    Capital expenditures$127.05K$0$456.80K$0$0N/A$0N/A$3$4
    Free cash flow-$28.78M-$28.17M-$24.58M-$23.74M-$12.48MN/A-$1.31MN/A-$4.95M-$1.91M
    Share repurchasesN/AN/AN/A$47.29K$10.23M$0N/AN/AN/AN/A
    Investing cash flow-$3.81M-$7.65M-$681.80K$0$0$0$0$1.35M-$590.50K$149.85K
    Financing cash flow$31.81M$45.45M$4.42M$3.95M-$3.74M$65.00M$1.17M$3.01M$5.29M$2.89M
    Fiscal years ended Jul 2017 to Jul 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$5.96M-$7.08M-$7.97M-$7.70M-$8.13M-$7.16M-$5.92M-$6.96M-$4.04M-$5.08M-$7.40M-$7.61M
    Capital expendituresN/A$129.18KN/AN/AN/AN/A$0$0$624.21K$0$0N/A
    Free cash flowN/A-$7.21MN/AN/AN/AN/A-$5.92M-$6.96M-$4.66M-$5.08M-$7.40MN/A
    Last 12 quarters

    Frequently Asked Questions About BCTX

    What is Briacell Therapeutics' annual revenue?

    Briacell Therapeutics reported revenue of $0 for the fiscal year ended Jul 31, 2026.

    Is Briacell Therapeutics profitable?

    No. Briacell Therapeutics reported net income of -$35.33M for the fiscal year ended Jul 31, 2026.

    How much free cash flow does BCTX generate?

    For the fiscal year ended Jul 31, 2026, operating cash flow of -$28.65M minus capital expenditures of $127.05K produced free cash flow of -$28.78M.

    How much debt does Briacell Therapeutics have?

    The balance sheet dated Jul 31, 2026 reported cash and equivalents of $9.85M.